Ceruloplasmin has two nearly identical sites that bind myeloperoxidase
Bakytzhan Bakhautdin1, Esen Goksoy Bakhautdin1, Paul L Fox2
1Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Basic Medical Sciences, School of Medicine, Fatih University, Istanbul, Turkey.
Abstract:
Ceruloplasmin (Cp) is a copper-containing ferroxidase with potent antioxidant activity. Cp is expressed by hepatocytes and activated macrophages and has been known as physiologic inhibitor of myeloperoxidase (MPO). Enzymatic activity of MPO produces anti-microbial agents and strong prooxidants such as hypochlorous acid and has a potential to damage host tissue at the sites of inflammation and infection. Thus Cp-MPO interaction and inhibition of MPO has previously been suggested as an important control mechanism of excessive MPO activity. Our aim in this study was to identify minimal Cp domain or peptide that interacts with MPO. We first confirmed Cp-MPO interaction by ELISA and surface plasmon resonance (SPR). SPR analysis of the interaction yielded 30nM affinity between Cp and MPO. We then designed and synthesized 87 overlapping peptides spanning the entire amino acid sequence of Cp. Each of the peptides was tested whether it binds to MPO by direct binding ELISA. Two of the 87 peptides, P18 and P76 strongly interacted with MPO. Amino acid sequence analysis of identified peptides revealed high sequence and structural homology between them. Further structural analysis of Cp's crystal structure by PyMOL software unfolded that both peptides represent surface-exposed sites of Cp and face nearly the same direction. To confirm our finding we raised anti-P18 antisera in rabbit and demonstrated that this antisera disrupts Cp-MPO binding and rescues MPO activity. Collectively, our results confirm Cp-MPO interaction and identify two nearly identical sites on Cp that specifically bind MPO. We propose that inhibition of MPO by Cp requires two nearly identical sites on Cp to bind homodimeric MPO simultaneously and at an angle of at least 120degrees, which, in turn, exerts tension on MPO and results in conformational change.
Insights
Ceruloplasmin (Cp) inhibits myeloperoxidase (MPO) by binding to two specific sites, P18 and P76. This interaction, crucial for controlling inflammation, involves simultaneous binding to MPO, leading to conformational changes and reduced MPO activity.
Area of Science:
- Biochemistry
- Immunology
- Molecular Biology
Background:
- Ceruloplasmin (Cp) is a copper-containing ferroxidase with antioxidant properties.
- Cp physiologically inhibits myeloperoxidase (MPO), an enzyme involved in inflammation that can damage host tissues.
- Understanding the Cp-MPO interaction is key to controlling excessive MPO activity.
Purpose of the Study:
- To identify the minimal domain or peptide of Cp that interacts with MPO.
- To elucidate the mechanism by which Cp inhibits MPO activity.
Main Methods:
- Confirmation of Cp-MPO interaction using ELISA and surface plasmon resonance (SPR).
- Synthesis and screening of 87 overlapping peptides spanning the Cp sequence for MPO binding.
- Structural analysis of Cp and identified peptides using PyMOL software.
- Disruption of Cp-MPO binding using anti-P18 antisera to assess MPO activity rescue.
Main Results:
- SPR analysis confirmed a high-affinity interaction (30nM) between Cp and MPO.
- Two peptides, P18 and P76, demonstrated strong binding to MPO, with high sequence and structural homology.
- Structural analysis revealed these peptides represent surface-exposed sites on Cp.
- Anti-P18 antisera disrupted Cp-MPO binding and restored MPO activity.
Conclusions:
- Cp interacts with MPO via two distinct, nearly identical surface sites (P18 and P76).
- The inhibition mechanism likely involves simultaneous binding of these two sites to homodimeric MPO.
- This simultaneous binding induces conformational changes in MPO, regulating its activity and mitigating potential host tissue damage.
More Related Videos
Related Concept Videos
Ligand Binding and Linkage
Drug Binding to Blood Components
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Gene Families
Occasionally these regions can be adapted to take on new roles within the organism, becoming novel genes...
Conserved Binding Sites
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
Metal-Ligand Bonds
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...


